The following is a guide to learn more about a number of clinical trials that are taking place at pharmaceutical and medical device companies who are a part of HOPA’s Industry Relations Council (IRC). To learn more about all active clinical trials, visit www.clinicaltrials.gov.

Iovance

• NSCLC – LUN-202 - A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung
• Solid Tumor Trial – NCT03645928 – A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
• Cervical Cancer - NCT03108495 - A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
• CLL/SLL - NCT04155710 - A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• Iovance Clinical Trials
• Iovance Clinical Trials

Servier

• Servier Clinical Trials

Morphosys

• Morphosys Clinical Trials

Lilly

• Clinical Trials by Therapeutic Target | Lilly Oncology (lillyloxooncologypipeline.com)

BeiGene

• Diverse Pipeline of Novel Therapies

BTG Specialty Pharmaceuticals

• Clinical Trials with glucarpidase in adult Osteosarcoma
• Clinical Trials with glucarpidase and CNS Lymphoma
• Clinical Trials with glucarpidase fir active or at high risk of CNS Lymphoma

ADC Therapeutics

• ADC Therapeutics Clinical Trials

Mirati

• Mirati Clinical Trials